Harmony Biosciences Holdings, Inc.
WAKIX
narcolepsy
Resolved
7days ago
Phase 3 readout · Jun 30, 2026
What's at stake
Phase 3 trial results for WAKIX in narcolepsy are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Pitolisant Franchise Strategy · WAKIX: On track to achieve blockbuster status in narcolepsy o Net revenue projected between $1.0 billion to $1.04 billion for the full year ending December 31, 2026 o Pitolisant in Prader-Willi Syndrome (PWS)”